First‐line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non‐squamous non‐small cell lung cancer with wild‐type driver genes: A real‐world study in China-Reference-Cited by-同舟云学术

First‐line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non‐squamous non‐small cell lung cancer with wild‐type driver genes: A real‐world study in China

Published:2019-03-22 Issue:5 Volume:10 Page:1043-1050
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Chang Qing¹^ORCID,Zhang Yanwei¹,Xu Jianlin¹,Zhong Runbo¹,Qiang Huiping¹,Zhang Bo¹,Han Baohui¹,Qian Jialin¹,Chu Tianqing¹^ORCID

Affiliation:

1. Pulmonary Department, Shanghai Chest HospitalShanghai Jiao Tong University Shanghai China

Funder

Western Medicine Guide Project of Shanghai Committee of Science and Technology

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13025

Reference28 articles.

1. Cancer statistics, 2018

2. Progress and prospects of early detection in lung cancer

3. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

4. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

5. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Treatment for Cervical Cancer: An Update;Anti-Cancer Agents in Medicinal Chemistry;2020-10-27

2. Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer;Cancers;2020-03-26

3. Effect and Mechanism of Interferon-Gamma Combined with Pembrolizumab on Chemoresistance of Lung Adenocarcinoma;Journal of Biomaterials and Tissue Engineering;2020-01-01